0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Should we treat during the prodromal phase? Con

Session 1: Migraine pathophysiology

Håkan Ashina

MD, PhD, Senior Researcher at Copenhagen University Hospital - Rigshospitalet, Denmark

Download presentation

Previous

Should we treat during the prodromal phase? Pro

You Might Also Like

Related Embedded Video Item Thumbnail Can we modify the course of migraine?
Related Embedded Video Item Thumbnail Navigating recent studies: A Nordic perspective
Related Embedded Video Item Thumbnail Pregnancy management and breastfeeding in migraine
Related Embedded Video Item Thumbnail Switching between anti-CGRP monoclonal antibodies and gepants
Related Embedded Video Item Thumbnail How to evaluate drug effectiveness in migraine?

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128